Daré Bioscience Initiates Phase 1/2 Clinical Study of DARE-HRT1

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. MSFT
8. MH
9. DLMAF
10. DOL:CN

Go back to Daré Bioscience Initiates Phase 1/2 Clinical Study of DARE-HRT1
(NASDAQ: DARE) Delayed: 2.05 +0.02 (0.99%)
Previous Close $2.03    52 Week High $ 
Open $2.03    52 Week Low $ 
Day High $2.05    P/E N/A 
Day Low $1.98    EPS $ 
Volume 14,938